The fusions involved a variety of genes that have been shown to contribute to MAPK signaling, thus likely phenocopying the effect of activating KRAS point mutations that are present in pancreatic adenocarcinoma in >90% of cases (The Cancer Genome Atlas Research Network 2017). The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.